Drug Information

Drug General Information
Drug ID
D09EFC
Former ID
DCL000018
Drug Name
CAP-232
Drug Type
Small molecular drug
Indication Refractory renal cell carcinoma [ICD9: 189; ICD10:C64] Phase 2a [522404]
Pain; Solid tumours [ICD9: 338, 356.0, 356.8, 780, 140-199, 210-229; ICD10:G64, G90.0, R52, G89, C00-D48] Phase 2 [522404]
Therapeutic Class
Anticancer Agents
Structure
Download
2D MOL

3D MOL
Formula
C45H58N10O9S2
Canonical SMILES
CC(C(C(=O)N)NC(=O)C1CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)<br />N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5<br />=CC=CC=C5)N)O
InChI
1S/C45H58N10O9S2/c1-25(56)38(39(48)58)55-45(64)37-24-66-65-23-36(53-40(59)31(47)19-26-9-3-2-4-10-26)44(63)51-34(20-27-14-16-29(57)17-15-27)42(61)52-35(21-28-22-49-32-12-6-5-11-30(28)32)43(62)50-33(41(60)54-37)13-7-8-18-46/h2-6,9-12,14-17,22,25,31,33-38,49,56-57H,7-8,13,18-21,23-24,46-47H2,1H3,(H2,48,58)(H,50,62)(H,51,63)(H,52,61)(H,53,59)(H,54,60)(H,55,64)/t25-,31-,33+,34+,35-,36+,37+,38+/m1/s1
InChIKey
SNAJPQVDGYDQSW-DYCFWDQMSA-N
PubChem Compound ID
6918265
PubChem Substance ID
12014851, 14865545, 14938834, 17194775, 43529648, 74779195, 103642514, 114787693, 124955647, 198967127, 241036850, 241377103, 249691248, 252158237
Target and Pathway
Target(s) Pyruvate kinase M2 Target Info Modulator [1572591]
References
Ref 522404ClinicalTrials.gov (NCT00735332) Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma. U.S. National Institutes of Health.
Ref 1572591Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.